A CBD Company Claimed Its Products Cured Anxiety and Chronic Pain. Where Was the Evidence?

As consumer interest in CBD products surged in the years following federal hemp legalization, Kushly Industries LLC and its CEO, Cody Alt, marketed a line of CBD products using health and establishment claims that, according to the Federal Trade Commission, were never substantiated by competent scientific evidence.DOCUMENTED

The FTC filed its complaint against Kushly Industries and Alt in May 2021, part of a broader wave of enforcement attention directed at the largely unregulated CBD marketplace that expanded rapidly after the 2018 Farm Bill removed hemp-derived CBD from the federal controlled substances list.DOCUMENTED

What the complaint alleges

According to the FTC's complaint, Kushly Industries and Alt marketed CBD products using health claims about the products' ability to address conditions such as anxiety and chronic pain, along with establishment claims asserting that scientific research or testing specifically supported those benefits.DOCUMENTED Establishment claims carry a distinct legal significance from general health claims: asserting that a product's benefits are scientifically established or clinically proven implies a specific evidentiary foundation that, if the underlying research does not actually exist or does not support the claim as stated, constitutes a more direct form of deception than a vaguer wellness assertion.REVIEWED

Why CBD marketing drew heightened scrutiny

CBD products occupy an unusual regulatory position: hemp-derived CBD with minimal THC content became federally legal to sell under the 2018 Farm Bill, but the FDA has not established a regulatory framework specifically governing health claims for CBD products the way it has for conventional over-the-counter drugs, leaving the FTC's general authority over unsubstantiated advertising claims as one of the primary federal tools available to address deceptive marketing in this specific product category.REVIEWED That regulatory gap, combined with rapidly growing consumer demand and limited independent research on CBD's actual effects for many commonly claimed uses, created conditions the FTC has treated as a priority enforcement area since the market's expansion began.

Why anxiety and pain claims specifically draw attention

Marketing a product as an effective treatment for anxiety or chronic pain carries particular weight because both conditions are commonly and legitimately treated through established medical interventions, including prescription medication and clinical therapy, and a consumer who believes an unregulated supplement is adequately addressing either condition may delay seeking the kind of evidence-based treatment that condition actually requires.REVIEWED That risk of delayed or foregone appropriate care is a recurring theme across FTC health-claims enforcement generally, distinguishing cases involving serious or chronic conditions from cases involving purely cosmetic or general wellness claims.

How the case proceeded

The FTC pursued the Kushly Industries matter through its administrative adjudication process, a track distinct from federal district court litigation that allows the Commission to resolve consumer protection matters through its own internal proceedings, culminating in a binding order enforceable in the same manner as a federal court judgment.REVIEWED

The complaint's establishment claims allegation — that specific scientific research backed the products' benefits — carries more legal weight than a vague wellness assertion, since it implies evidence that, according to the FTC, simply did not exist.

Why the case matters

For consumers navigating the still-expanding CBD marketplace, the Kushly Industries case is a reminder that claims framed as scientifically established or clinically proven deserve particular scrutiny, since federal law treats an unsupported establishment claim as a more serious violation than a vaguer wellness assertion — and that the FDA's limited regulatory framework for CBD products means the FTC's general advertising-substantiation authority remains one of the few checks currently available against unsupported health claims in this specific product category.

Why the CBD market attracted so many similar claims at once

Following the 2018 Farm Bill's legalization of hemp-derived CBD, thousands of new companies entered the market within a short window, many marketing products with similar claims about anxiety relief, pain management, and other therapeutic benefits, often based on the same limited body of preliminary research rather than product-specific clinical testing.REVIEWED That rapid, largely unregulated market expansion created conditions where establishment claims — asserting that specific research validated a specific product — became common marketing shorthand across the industry, frequently applied more broadly than the underlying research, often conducted on isolated CBD compounds rather than finished consumer products, actually supported.

What a substantiated establishment claim would actually require

To lawfully make an establishment claim, a company generally needs the type of scientific evidence that experts in the relevant field would consider sufficient to support the specific claim being made, typically including well-controlled human clinical studies conducted on the actual product or a substantially similar formulation, not merely general research on an ingredient in isolation.REVIEWED The gap between that evidentiary standard and what many CBD marketers, including the defendants in this case, actually possessed is precisely the violation the FTC's complaint describes. That gap is often invisible to an ordinary shopper reading a product label, which is exactly why federal advertising-substantiation rules place the burden on the seller, not the buyer, to have the evidence in hand before making the claim at all.

Consumers can also check whether a company's cited research was actually conducted on the specific product being sold, rather than on an unrelated formulation or an isolated compound tested under different conditions entirely.

Asking a company directly for its supporting research, rather than accepting a general reference to “studies show,” remains one of the simplest ways a consumer can test whether an establishment claim actually holds up.

A company confident in its evidence will typically provide it without hesitation; one that deflects the question is telling a consumer something important on its own.

Have documents relevant to this story? Reach us through our tips channel.